Be The Match BioTherapies presents at Phacilitate Cell & Gene Therapy World 2017
Be The Match BioTherapiesSM and our parent company, National Marrow Donor Program® (NMDP)/Be The Match® participated in the Phacilitate Cell & Gene Therapy World 2017 in Miami, Fla.
During the conference, Be The Match BioTherapies released the white paper, “Exceptions are the Norm: The importance of patient case management to reduce variability in cell therapy supply chains.” The white paper complemented a presentation by Molly McCormick, MA, CHTC, vice president of Case Management and Operations Services at NMDP/Be The Match.
McCormick presented “The importance of patient case management in building and operating a cell supply chain” on Wednesday, Jan. 18. Her presentation was part of the session, “Addressing key remaining questions around initial patient cell collection and delivery to the bioprocessing facility at commercial sale.”
On Friday, Jan. 20, Michael Boo, JD, chief strategy officer at NMDP/Be The Match, took part in the panel discussion, “Opening overviews defining the current cord blood and tissue sector and marketplace.”
About Be The Match BioTherapies
We partner with organizations pursuing new life-saving treatments in cellular therapy. Built on the foundation established over the last 30 years by the NMDP/Be The Match, we have unparalleled experience in personalized case management with a single point of contact, cell sourcing and collection, cell supply chain, immunogenetics and bioinformatics, research, and regulatory compliance.
By leveraging our proven capabilities and established relationships, we can bring customizable solutions to organizations in every stage of cellular therapy development — from discovery through commercialization. Discover how Be The Match BioTherapies can assist your company at BeTheMatchBioTherapies.com.